Carbon monoxide lowers IOP

Article

CORM-3, a water-soluble carbon monoxide-releasing molecule, is associated with a intraocular pressure (IOP) lowering in animal models of ocular hypertension, concluded a study published in the January issue of the British Journal of Ophthalmology.

CORM-3, a water-soluble carbon monoxide-releasing molecule, is associated with intraocular pressure (IOP) lowering in animal models of ocular hypertension, concluded a study published in the January issue of the British Journal of Ophthalmology.

Professor F Drago of the University of Catania Medical School, Catania, Italy and colleagues injected [alpha]-chymotrypsin into rabbit eyes to induce ocular hypertension, and then assessed the effects of administering CORM-3 at doses of 0.001, 0.01, 0.1 and 1%. In a separate trial arm, the team induced ocular hypertension through subconjunctival betamethasone injections and administered CORM-3. In each trial arm, control subjects were treated with inactive CORM-3 (iCORM-3).

In both trial arms, administration of CORM-3 was associated with a reduction in IOP; dosage amount was positively correlated with the amount of IOP reduction. The control subjects experienced no IOP reduction.

The researchers therefore concluded that CORM-3 is associated with a reduction of IOP in two separate animal models of induced ocular hypertension. This correlation between carbon monoxide modulation and IOP has been established by previous studies.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Jeremiah Tao, MD, FACS, discusses his Egyptian Ophthalmological Society keynote, which focused on risk management and avoiding surgical complications in oculofacial surgery
Omer Trivizki, MD, MBA, a retina specialist from Tel Aviv Medical Center, speaks about VOY-101, a Novel, Complement-Modulating Gene Therapy for Geographic Atrophy at the American Society of Retina Specialists (ASRS) Annual Meeting
João Pedro Marques, MD, MSc, PhD discusses a retrospective study of 800 patients with inherited retinal diseases during the American Society of Retina Specialists (ASRS) annual meeting
© 2025 MJH Life Sciences

All rights reserved.